Navigation Links
Inhaled Steriods Used as Preventive Treatment Post 9/11
Date:10/24/2007

Popular Asthma Medication Linked to Respiratory Improvement in NYC

Firefighters

CHICAGO, Oct. 24 /PRNewswire/ -- Inhaled corticosteroids (ICS), antiinflammatory treatments often prescribed for asthma, may be beneficial in preventing respiratory illness, according to a new study. The research, presented at CHEST 2007, the 73rd annual international scientific assembly of the American College of Chest Physicians (ACCP), examined the effectiveness of ICS in preventing asthma and other respiratory illness due to inhalation exposures experienced by NYC firefighters after the World Trade Center (WTC) collapse. Two years post-collapse, those firefighters treated with ICS reported positive feedback.

"Respiratory protection is often needed during disasters, but it is difficult to get it instantly, and many responders, without EMS or fire experience, have not been trained or fit-tested to wear equipment properly. Couple this with a disaster environment that is difficult in which to function, and it leads to exposures that could result in lung damage," said study author David Prezant, MD, FCCP, Chief Medical Officer, Office of Medical Affairs and Co-Director WTC Medical Monitoring and Treatment Programs, New York City Fire Department. "However, our preliminary data suggest that combining prophylactic inhaled corticosteroids with our best attempts to provide proper respiratory protection could reduce declines in lung function."

One week post-WTC attack, Dr. Prezant and his colleagues from the New York City Fire Department offered ICS to NYC firefighters. Participating firefighters were told to use the ICS inhaler daily for 4 weeks. Two years post-WTC collapse, Dr. Prezant and coinvestigators from Montefiore Medical Center, New York University College of Medicine, and the Shaare Zedek Medical Center in Israel, offered free, voluntary evaluations of respiratory symptoms and function to the treated firefighters and a comparison group of firefighters who did not participate in the ICS treatment but who were matched for similar exposures and pretreatment pulmonary function.

A total of 2,708 firefighters agreed to participate, but only 158 completed the 4 weeks of treatment (participant totals have been revised since abstract submission). Those who did not complete the treatment cited fear of steroid use and lack of immediate effect. Despite reporting more unprotected hours without a respirator, results showed that the treated group had significantly greater declines in respiratory symptoms and greater quality of life when compared with the untreated firefighters. In addition, revised data analysis showed a small but significant improvement in the lung function of the treated group, as well.

"In situations like the World Trade Center collapse, significant exposure and symptoms are both risk factors for the development of multiple pulmonary disorders," said Dr. Prezant. "The first line of defense must always be respiratory protection, but ICS are a useful adjunct, and we would encourage their use to be considered during emergency conditions where rescues must be made and respiratory protections may be less than adequate, or when early symptoms occur."

"Respiratory illness continues to plague those who were present when the World Trade Center collapsed," said Alvin V. Thomas, MD, FCCP, President of the American College of Chest Physicians. "It is essential that physicians and researchers work to alleviate and eventually cure those ailments caused by this tragedy, as well as any respiratory diseases that may be acquired in other occupational settings."

While researchers are optimistic about the results, they continue to stress that larger studies are required to substantiate these findings. This study was conducted with support from the Investigator-Sponsored Study Program of AstraZeneca, and the use of inhaled corticosteroids may be considered off- label use. The sponsors had no involvement in the design and conduct of the study, in the collection, management, analysis, and interpretation of the data, or in the preparation of this report.

CHEST 2007 is the 73rd annual international scientific assembly of the American College of Chest Physicians, held October 20-25 in Chicago, IL. The ACCP represents 17,000 members who provide patient care in the areas of pulmonary, critical care, and sleep medicine in the United States and throughout the world. The ACCP's mission is to promote the prevention and treatment of diseases of the chest through leadership, education, research, and communication. For more information about the ACCP, please visit the ACCP Web site at http://www.chestnet.org.


'/>"/>
SOURCE American College of Chest Physicians
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. PARI Pharma Presents Study Results of Sinus Delivery and Inhaled Liposomal Ciclosporin A at European Cystic Fibrosis Conference
2. PARI and Kamada Announce Positive Intermediate Phase I Results for Inhaled Alpha-1 Antitrypsin
3. Nektar Threraputics Announces Phase 2a Clinical Results Regarding the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative Hospital-Acquired Pneumonia Presented at the Annual American Thoracic Society International Conference
4. Clinical Trial Data (Phase 2a) Regarding Inhaled Amikacin Will Be Presented at American Thoracic Society International Conference
5. Baxter Presents Phase I Inhaled Insulin Study Results at Respiratory Drug Delivery Conference
6. Onconase has Potential as Chemopreventive Agent in Mesothelioma, Reports World-Renowned Mesothelioma Researcher at AACR Annual Meeting
7. Point of Care Strep Tests Speed Treatment, Lower Costs
8. Rapid HIV Testing Increases Possibility of Treatment
9. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
10. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)...  Visage Imaging Inc. ("Visage"), a wholly owned ... that the American College of Radiology (ACR) and ... Visage 7 Enterprise Imaging Platform as the new ... SIMulation (SIM). SIM is the assessment component of ... multi-faceted and fully-integrated online assessment, education and remediation ...
(Date:2/10/2016)... -- CERS ), Medivation, Inc. (NASDAQ: MDVN ... Therapeutics, Inc. (NASDAQ: CLDX ). --> CERS ... (NASDAQ: ADMS ) and Celldex Therapeutics, Inc. (NASDAQ: ... become vitally important in the development of targeted treatment therapies ... which are defined as those intended for the safe and ...
(Date:2/10/2016)... Israel , February 10, 2016 /PRNewswire/ ... leader in the field of cartilage repair, announces the ... 5, 2016. The $15 million investment was led by ... pharmaceutical manufacturer, and was joined by existing Regentis investors ... and both the Technion Research & Development Foundation and ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... Ongoing news of the ravages of traumatic ... to conduct a survey that takes a closer look at cases of TBI being ... and causes of TBI among the aging population, and identifies the challenges associated with ...
(Date:2/10/2016)... ... February 10, 2016 , ... Armune BioScience signed ... their network of laboratory service centers across the country. Launched in April of 2015, ... the detection of prostate cancer. Apifiny order volume exceeded 3,000 tests in 2015. Primary ...
(Date:2/10/2016)... ... February 10, 2016 , ... The Club at ... the prestigious Distinguished Emerald Club of the World award, as determined by the ... of the most respected trade publications serving private clubs. , “We’d like to ...
(Date:2/10/2016)... ... 10, 2016 , ... Workrite Ergonomics, who is celebrating their 25th year of ... to being an internationally recognized leader in their industry. , "We are very proud ... President of Workrite. “Workrite recognized the importance of good ergonomics before most of ...
(Date:2/10/2016)... ... February 09, 2016 , ... Ross A. ... are delighted to welcome a new addition to their growing practice. Beginning this ... as a nurse practitioner performing cosmetic procedures including injectables, fillers and ...
Breaking Medicine News(10 mins):